

ERRATUM

Erratum to: Chordoma: The Quest for Better Treatment Options

Christopher R. Heery

To view enhanced content go to www.oncologytherapy-open.com

Received: March 24, 2016 / Published online: April 20, 2016

© The Author(s) 2016. This article is published with open access at Springerlink.com

Erratum to: Oncol Ther
DOI 10.1007/s40487-016-0016-0

The author of the above mentioned paper have noticed a mistake in Table 1 following publication and wish to make the following correction.

The reference for the lapatinib study should be 36 (Stacchiotti S, Tamborini E, Lo Vullo S, et al. Phase II study on lapatinib in advanced

EGFR-positive chordoma. *Ann Oncol.* 2013;24:1931–6), and the reference for the 9-nitro-camptothecin study should be 43 (Chugh R, Dunn R, Zalupski MM, et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. *J Clin Oncol.* 2005;23:3597–604).

The corrected Table 1 can be found below.

The online version of the original article can be found under doi:[10.1007/s40487-016-0016-0](https://doi.org/10.1007/s40487-016-0016-0).

C. R. Heery (✉)
Laboratory of Tumor Immunology and Biology,
Center for Cancer Research, National Cancer
Institute, National Institutes of Health, Bethesda,
MD 20892, USA
e-mail: heerycr@mail.nih.gov

Table 1 Summary of systemic therapy data

Therapy	Target	Number of chordoma patients	Reported results	Study design	References
Imatinib	PDGFR	50	1 PR (RECIST); 35 SD; median PFS = 9 months (RECIST)	Single-arm phase II trial	Stacchiotti et al. [32]
Imatinib	PDGFR	17	0 PR; 17 SD	Case series	Ferraresi et al. [33]
Lapatinib	EGFR	18	13 SD; 6 PR (Choi); 0 PR (RECIST); median PFS = 8 months (RECIST)	Single-arm phase II trial	Stacchiotti et al. [36]
Erlotinib	EGFR	1	1 PR	Case report	Singhal et al. [37]
Erlotinib + bevacizumab	EGFR, VEGF	3	3 SD	Case report	Asklund et al. [38]
Ceruximab + gefitinib	EGFR	1	1 PR	Case report	Hof et al. [39]
Ceruximab + gefitinib	EGFR	1	1 PR	Case report	Linden et al. [40]
Sorafenib	Multiple	27	1 PR (RECIST); 9-month PFS = 73.0%; 12-month OS = 86.5%	Single-arm phase II trial	Bompas et al. [41]
9-Nitro-camptothecin	Topoisomerase I	15	1 PR (RECIST); median PFS = 9.9 months	Single-arm phase II trial	Chugh et al. [43]
Thalidomide	Multiple	1	1 PR	Case report	Chay et al. [44]
GI-6301 (recombinant yeast-brachyury vaccine)	Brachyury	11	1 PR (RECIST); 1 mixed response (RECIST); median PFS = 8.3 months	Phase I trial	Heery et al. [65]

Table is modified with permission from <http://www.chordomafoundation.org/systemic-therapy/>
 PR partial response, PFS progression-free survival, RECIST Response Evaluation Criteria in Solid Tumors, SD stable disease

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-commercial use, distribution, and reproduction

in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.